STAT1 plays a role in TLR signal transduction and inflammatory responses

Immunology and Cell Biology

Volumn 92, Issue 9, 2014, Pages 761-769

  Luu, Kevin ^a   Greenhill, Claire J ^a   Majoros, Andrea ^b   Decker, Thomas ^b   Jenkins, Brendan J ^a   Mansell, Ashley ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; RANTES; STAT1 PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; CCL5 PROTEIN, MOUSE; IRF3 PROTEIN, MOUSE; IRF7 PROTEIN, MOUSE; JANUS KINASE; STAT1 PROTEIN, MOUSE; TICAM-1 PROTEIN, MOUSE; TOLL LIKE RECEPTOR; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BONE MARROW DERIVED MACROPHAGE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HYPERSENSITIVITY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CELL CULTURE; IMMUNOLOGY; MACROPHAGE; PHOSPHORYLATION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CELLS, CULTURED; CHEMOKINE CCL5; INFLAMMATION; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; INTERLEUKIN-6; JANUS KINASES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908160577     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.51     Document Type: Article

References (31)

1. O'Neill LAJ. How Toll-like receptors signal: What we know and what we don't know. Curr Opin Immunol 2006; 18: 3-9.
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
3. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H e t al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 2003; 301: 640-643.
4. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO et al. Identification o f Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424: 743-748.
5. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E et al. LPS-TLR4 signalin g to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003; 198: 1043-1055.
6. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
7. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-787.
8. Greenhill CJ, Gould J, Ernst M, Jarnicki A, Hertzog PJ, Mansell A et al. LPS hypersensitivity of gp130 mutant mice is independent of elevated haemopoietic TLR4 signaling. Immunol Cell Biol 2012; 90: 559-563.
9. Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ et al. IL-6 transsignaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2011; 186: 1199-1208.
10. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8: 1089-1097.
11. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-Associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738.
12. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS et al. Targeted disruption of the Stat1 gene in mice rev eals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431-442.
13. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 2001; 69: 598-604.
14. Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFNgamma-dependent innate immunity. Immunity 2003; 19: 793-802.
15. Rhee SH, Jones BW, Toshchakov V, Vogel SN, Fenton MJ. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem 2003; 278: 22506-22512.
16. Schroder K, Spille M, Pilz A, Lattin J, Bode KA, Irvine KM et al. Differential effects of CpG DNA on IFN-bet a induction and STAT1 activation in murine macrophages versus dendritic cells: alternatively activated STAT1 negatively regulates TLR signaling in macrophages. J Immunol 2007; 179: 3495-3503.
17. Hornung V, Ba uernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847-856.
18. Nguyen H, Chatterjee-Kishore M, Jiang Z, Qing Y, Ramana CV, Bayes J et al. IRAKdependent phosphorylation of Stat1 on serine 727 in response to interleukin-1 and effects on gene expression. J Interferon Cytokine Res 2003; 23: 183-192.
19. Decker T, Kovarik P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci 1999; 55: 1535-1546.
20. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19: 2628-2637.
21. Wietek C,Miggin SM,Jefferies CA,O'Neill LA. Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa J Biol Chem 2003, 278, 50923-50931.
22. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169: 6668-6672.
23. Mansell A, Brint E, Gould JA, O'Neill LA, Hertzog PJ. Mal interacts with tumor necrosis factor receptor-Associated factor (TRAF)-6 to mediate NF-kappaB acti vation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem 2004; 279: 37227-37230.
24. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, M ansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2-And TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem 2009; 284: 24192-24203.
25. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-Associated factor 6 and TANK-binding kinase 1, and activates two distinct transcripti on factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003; 171: 4304-4310.
26. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERKdependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997; 17: 6508-6516.
27. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ e t al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006; 7: 148-155.
28. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGFbeta signaling. Nat Med 2005; 11: 845-852.
29. Hirschfeld M, Ma Y , Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165: 618-622.
30. Close B, Banister K, Baumans V, Bernoth EM, Bromage N, Bunyan J et al. Recommendations for euthanasia of experimental animals: Part 2. DGXT of the European Commission. Lab Anim 1997; 31: 1-32.
31. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001; 16 6: 6633-6639.